Prediction of the effectiveness and safety of nivolumab for non-small cell lung cancer patients: a retropective cohort study

Prediction of the effectiveness and safety of nivolumab for non-small cell lung cancer patients: a retropective cohort study - The effectiveness and safety of nivolumab for non-small cell lung cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022014

Enrollment

200

Registered

2016-04-21

Start date

2016-04-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically confirmed advanced non-small cell lung cancer Treated with nivolumab after second line from 1/2016 to the date of institutional review board approval

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Secondary

Measure	Time frame
adverse events response rate overall survival	—

Countries

Japan

Contacts

Public ContactYuki Kataoka

Hyogo Prefectural Amagasaki General Medical Center Department of Respiratory Medicine

youkitikk@gmail.com06-6480-7000

Outcome results